SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) ...
Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues. Find out why ZLAB stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results